Skip to main content
news
A Takeda logo is seen in its research hub in Cambridge, Massachusetts, U.S., November 26, 2018. REUTERS/Julie Steenhuysen

Cleary Gottlieb Steen & Hamilton has advised Japanese pharmaceutical giant Takeda on its planned acquisition of U.S.-based Nimbus Therapeutics' experimental psoriasis drug, with Goodwin Procter acting for the seller.

The deal value is expected to be up to $6 billion, reported Reuters. It added that the drug, codenamed "NDI-034858", has shown statistically significant reduction in moderate-to-severe psoriasis in a mid-stage study and is expected to enter late-stage trials next year.

The Goodwin team was led by partners Bill Collins, Sarah Solomon and Yasin Akbari in Boston, and Erini Svokos in New York.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Trilegal, Khaitan guide RMZ-Colt $1.7 bln India data centre JV

by Nimitt Dixit |

Trilegal advised Indian alternative asset owner RMZ Group on its $1.7 billion joint venture with Colt Data Centre Services, which was advised by Khaitan & Co, to invest in the Indian data centre market, as well as the proposed acquisition of stakes in two data centre projects.

Deals

HSF, CC lead on SF Holdings’ $750 mln Hong Kong IPO

by Hu Yangxiaoxiao 胡阳潇潇 |

Herbert Smith Freehills, CM Law Firm, and Grandall Law Firm have advised Chinese logistics provider SF Holdings on its $750 million initial public offering in Hong Kong, with Clifford Chance and King & Wood Mallesons advising the joint sponsors.

Deals

Bakers, HSF act on PE acquisition of Japan’s jinjer

by Nimitt Dixit |

Baker & McKenzie (Gaikokuho Joint Enterprise) has advised private equity firms J-STAR Co and Potentia Capital on their joint acquisition of jinjer, one of Japan’s leading HR SaaS players. While financial terms were not recorded, news reports value the deal at $500 million.